Beaconlight Capital LLC Sells 14,874 Shares of TransMedics Group, Inc. $TMDX

Beaconlight Capital LLC lessened its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 33.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,344 shares of the company’s stock after selling 14,874 shares during the quarter. TransMedics Group makes up approximately 2.1% of Beaconlight Capital LLC’s investment portfolio, making the stock its 17th largest position. Beaconlight Capital LLC owned 0.09% of TransMedics Group worth $3,570,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $29,000. Allworth Financial LP grew its position in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Optiver Holding B.V. grew its position in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares during the period. Parallel Advisors LLC grew its position in TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the period. Finally, LOM Asset Management Ltd acquired a new stake in TransMedics Group in the 3rd quarter valued at $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $73.22 on Thursday. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The business has a 50 day moving average of $84.57 and a 200 day moving average of $113.51. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of 16.64 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the previous year, the firm posted $0.70 EPS. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen decreased their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Piper Sandler decreased their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Needham & Company LLC reduced their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $134.00.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.